Popular search terms:
Search Results
21 results found-
World Haemophilia Day
CSL Behring Marks World Haemophilia Day by Shipping Bleeding Disorders Medicines to the World Federation of Haemophilia
https://www.cslbehring.com.au/...nts-in-the-developing-world -
R&D Investor Briefing 2015
Commercial Opportunities Bob Repella . Q&A Break . Coagulation/Haemophilia . Clinical Medicines Specialty Products Haemophilia Products CSL Protein Therapeutics
https://www.cslbehring.com.au/-/media/shared/documents/7/rd-investor-briefing-2015.pdf -
Australia
With Alpha-1 deficiency CSL Behring Australia Haemophilia Foundation Australia Contribution in support of Haemophilia Foundation Australia (HFA) Patient Conference CSL
https://www.cslbehring.com.au/-/media/cslb-australia/documents/transparency-reports/csl-bhering-hcp-transparency-report-2015-pdf.pdf -
MonoFIX-VF
The information in this leaflet is subject to change. Please check with your haemophilia MonoFIX ® -VF is used in patients with haemophilia B or Christmas disease, a bleeding
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/monofixvf-au-cmi-2001.pdf -
Newsroom
CSL Behring Australia is a biopharmaceutical leader driven by its promise to save and improve lives. We manufacture remedies for rare and serious conditions.
https://www.cslbehring.com.au/news/newsroom -
Biostate
The information in this leaflet is subject to change. Please check with your Haemophilia Biostate ® is also used in patients with haemophilia A, a bleeding disorder, in which
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/biostate-au-cmi-v2400.pdf -
R&D Investor Briefing 2016
Commercial Opportunities Bob Repella . Q&A - Break - . Coagulation/Haemophilia . Clinical registered products Core Capabilities: Haemophilia Immunoglobulins Specialty Products
https://www.cslbehring.com.au/-/media/shared/documents/7/rd-investor-briefing-2016.pdf -
News
CSL Behring Australia is a biopharmaceutical leader driven by its promise to save and improve lives. We manufacture remedies for rare and serious conditions.
https://www.cslbehring.com.au/news -
R&D Investor Briefing 2017
Early Development Charmaine Gittleson . Immunoglobulins, Haemophilia and Specialty Cycle Management # Immunoglobulins Haemophilia Specialty Products Influenza Vaccine
https://www.cslbehring.com.au/-/media/shared/documents/7/rd-investor-briefing-2017.pdf -
PowerPoint Presentation
Research & Early Development Andrew Nash . Commercial Market Overview, Ig & Haemophilia Core Capabilities: Immunoglobulins | Haemophilia | Specialty Products | Breakthrough
https://www.cslbehring.com.au/-/media/shared/documents/7/rd-investor-briefing-2018.pdf